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Abstract
Objective The prevalence of pulmonary disease caused
by nontuberculous mycobacteria (NTM) has been
increasing in Japan. Adjuvant resectional surgery is often
recommended to lessen disease progression when the
response to drug therapy is poor. In all likelihood, as
affected cases of NTM disease increase, so will the number
of operations. The goal of this study was to determine the
current status of NTM surgery in Japan by analyzing data
from the annual survey of the Japanese Association for
Thoracic Surgery (JATS).
Methods Data were obtained from annual surveys con-
ducted between 2008 and 2012. The annual number of
operations for pulmonary NTM disease was tabulated
nationwide and in each region (Hokkaido, Tohoku, Kanto,
Tokyo, Chubu, Kinki, Chugoku/Shikoku, and Kyushu). For
comparison, the numbers for pulmonary tuberculosis and
tuberculoma operations were also obtained.
Results The annual number of operations for pulmonary
NTM disease nationwide increased each year between
2008 and 2012: 292 (2008), 323 (2009), 452 (2010), 440
(2011), and 514 (2012); an overall increase of 76 %.
Conversely, the annual numbers of operations for pul-
monary tuberculosis were stable: 145 (2008), 181 (2009),
117 (2010), 113 (2011), and 107 (2012), as were the annual
numbers of operations for tuberculoma: 386 (2008), 341
(2009), 320 (2010), 390 (2011), and 351 (2012).
Conclusion Data from the JATS annual survey demon-
strate a steady increase in the number of NTM surgeries in
Japan. General thoracic surgeons will continue to increas-
ingly encounter NTM patients who are candidates for
surgery until a magic bullet against NTM disease is
available.
Keywords Nontuberculous mycobacteriosis 
Tuberculosis  Tuberculoma  Resectional surgery
Introduction
Since the advent of potent anti-tuberculous drugs, the
prevalence of pulmonary tuberculosis has been decreasing
in Japan. In contrast, it is thought that the prevalence of
pulmonary disease caused by nontuberculous mycobacteria
(NTM) has been increasing. The estimated incidence rate
of pulmonary NTM disease in Japan has increased from 1.5
per 100,000 in 1985 to 3.52 in 1997 [1]. NTM disease is
usually indolent, but can result in extensive parenchymal
destruction, causing respiratory failure and vulnerability to
airway infection, which can be fatal [2]. According to the
statement published by the American Thoracic Society
(ATS)/Infectious Diseases Society of America (IDSA) in
2007, the primary treatment for pulmonary NTM disease is
chemotherapy using a multidrug regimen [3]. However,
chemotherapy has limited efficacy in pulmonary diseases
caused by the majority of NTM species. Therefore, the
statement proposed a multidisciplinary treatment approach,
i.e., combined multidrug treatment regimen and adjuvant
resectional surgery, for patients with intractable pulmonary
NTM disease. The Japanese Society for Tuberculosis
(JST) published guidelines for surgical intervention of
pulmonary NTM disease in 2008, which recommended a
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multidisciplinary treatment approach consistent with the
2007 ATS/IDSA statement [4]. The higher the prevalence
of pulmonary NTM disease, the more likely the number of
operations for this disease will increase. This study was
designed to clarify the current status of NTM surgery in
Japan by analyzing data from the annual survey of the
Japanese Association for Thoracic Surgery (JATS).
Materials and methods
Data from the JATS annual survey conducted between
2008 and 2012 were used in this analysis. The year 2008
was used as a starting point because it was the year that
survey questionnaires added the category of pulmonary
NTM disease. The number of survey questionnaire forms
that were sent out to officially certified institutions
nationwide and their response rates in each year were as
follows: 785/95.3 % in 2008 [5], 798/96.5 % in 2009 [6],
787/97.2 % in 2010 [7], 790/95.6 % in 2011 [8], and
802/96.9 % in 2012 [9]. The total numbers of general
thoracic operations in each year were 61,315 in 2008 [5],
65,897 in 2009 [6], 67,960 in 2010 [7], 69,223 in 2011 [8],
and 72,899 in 2012 [9]. The annual number of operations
over the 5-year period for pulmonary NTM disease,
regionally (Hokkaido, Tohoku, Kanto, Tokyo, Chubu,
Kinki, Chugoku/Shikoku, and Kyushu) and nationwide,
was extracted from the JATS annual survey database that
comprises anonymized raw data. Data on the total number
of operations for pulmonary tuberculosis and tuberculoma
were also obtained for comparison.
Results
Nationally, the number of operations for pulmonary NTM
disease in 2012 increased 76 % over the number performed
in 2008 (Table 1). The ratio of the number of operations
for pulmonary NTM disease to the total number of general
thoracic operations also increased from 0.5 % (292/61,315)
in 2008 to 0.7 % (514/72,899) in 2012. Regionally, an
increase in NTM surgeries was particularly noted in
Tohoku, Kanto, Tokyo, Chubu, Kinki, and Chugoku/Shi-
koku. In contrast, the annual number of operations per-
formed for pulmonary tuberculosis (Table 2) and
tuberculoma (Table 3) was stable during the 5-year period.
Discussion
Nontuberculous mycobacteria are environmental organ-
isms found in soil and water that can produce opportunistic
lung infections. The true incidence and prevalence of
pulmonary NTM disease remains unclear because this
disease is not communicable and has not been designated a
reportable disease by the Ministry of Health, Labour, and
Welfare in Japan. However, reports suggest that the
prevalence of pulmonary NTM disease has been increasing
[1, 2]. Of 120? species of mycobacteria classified as NTM,
only a few are known to lead to pulmonary disease [3]. In
Japan, members of the Mycobacterium avium complex
(MAC) are the most common source of pulmonary NTM
disease [10]. Mycobacterium kansasii is the second most
common NTM, but the incidence ofM. kansasii pulmonary
disease is much lower than that of pulmonary MAC disease
[10]. Furthermore, a M. kansasii pulmonary infection is the
only NTM disease that can be successfully treated with a
multidrug regimen alone [3, 10]. Therefore, in daily clin-
ical practice, physicians are more likely to be consulted
about surgical intervention for pulmonary MAC disease.
The problem is that there is no specific agent for the
treatment of pulmonary MAC disease. Although the ATS
has recommended a multidrug regimen employing the
newer macrolides (clarithromycin or azithromycin),
rifampicin or rifabutin, ethambutol and, if necessary,
injectable aminoglycoside (streptomycin) [11], the efficacy
of this program remains limited. Kobashi and Matsushima
reported that the combined therapy for pulmonary MAC
disease recommended in the ATS [11] and the JST [12]
guidelines produced unsatisfactory results compared to the
Table 1 Annual trend of




Region 2008 [5] 2009 [6] 2010 [7] 2011 [8] 2012 [9]
Hokkaido 12 18 26 16 13
Tohoku 16 19 37 28 39
Kanto 54 62 96 72 86
Tokyo 33 57 53 72 90
Chubu 40 58 69 83 78
Kinki 72 45 68 67 95
Chugoku/Shikoku 32 46 60 52 75
Kyushu 33 18 43 50 38
Nation (total) 292 323 452 440 514
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clinical effect of the standard multidrug regimen for the
treatment of pulmonary tuberculosis [13]. The 2007 ATS/
IDSA statement recommended a multidisciplinary treat-
ment approach to prevent disease progression: a combi-
nation of chemotherapy and adjuvant resectional surgery
for patients with intractable NTM disease [3]. The JST
guidelines also recommended this multidisciplinary treat-
ment approach [4].
In this study, data from the JATS annual survey
revealed a steady increase in the annual number of oper-
ations performed in Japan for pulmonary NTM disease.
The overall number increased by 76 % in 5 years. How-
ever, the annual number of operations for pulmonary
tuberculosis was stable, as was the annual number of
operations for tuberculoma in the country. The total
number of general thoracic operations increased during the
study period. However, the increase in the number of
operations for pulmonary NTM disease cannot be
explained simply by the increase in the number of total
operations, because the ratio of the number of operations
for pulmonary NTM disease to the total number of general
thoracic operations also increased. The recent increase in
the number of operations for pulmonary NTM disease may
reflect the fact that the prevalence of pulmonary NTM
disease has been increasing in Japan and that the 2007
ATS/IDSA statement and the 2008 JST guidelines have
encouraged Japanese physicians to liberally apply adju-
vant resectional surgery to patients with pulmonary NTM
disease. This trend is expected to continue indefinitely.
Japanese General Thoracic surgeons will continue to
increasingly encounter NTM patients who are candidates
for resectional surgery until a magic bullet against this
intractable disease is available. A notable increase in the
number of operations for pulmonary NTM disease was
seen in six of the eight regions. Further investigation is
needed to clarify a regional distribution of patients with
pulmonary NTM disease in Japan.
Data from the JATS survey did not contain crucial
information (e.g., as patient characteristics, including age,
gender, NTM species, and disease type) that would have
allowed a more precise analysis of the current status of
NTM surgery. The data also lacked information on the
duration of pre-operative chemotherapy, the type of pul-
monary resection, and the duration of post-operative
chemotherapy. Pulmonary MAC disease predominantly
occurs in middle-aged women, and consists of two radio-
graphically characteristic features: fibrocavitary disease
and nodular/bronchiectatic disease [3]. Although MAC
disease is the NTM disease most likely to require pul-
monary resection, other less common NTM diseases, such
as Mycobacterium abscessus disease, which is notoriously
resistant to chemotherapeutic regimens, may also be
Table 2 Annual trend of
number of national and regional
operations for pulmonary
tuberculosis
Region 2008 [5] 2009 [6] 2010 [7] 2011 [8] 2012 [9]
Hokkaido 5 13 6 8 2
Tohoku 4 4 4 6 1
Kanto 20 33 29 20 23
Tokyo 20 42 13 23 19
Chubu 8 19 17 9 14
Kinki 49 44 19 27 23
Chugoku/Shikoku 18 12 11 10 8
Kyushu 21 14 18 10 17
Nation (total) 145 181 117 113 107
Table 3 Annual trend of
number of national and regional
operations for tuberculoma
Region 2008 [5] 2009 [6] 2010 [7] 2011 [8] 2012 [9]
Hokkaido 24 34 17 18 14
Tohoku 30 30 38 28 19
Kanto 73 77 64 81 96
Tokyo 57 45 35 55 30
Chubu 53 48 31 46 49
Kinki 89 67 87 77 86
Chugoku/Shikoku 27 26 24 47 34
Kyushu 33 14 24 38 23
Nation (total) 386 341 320 390 351
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subject to resectional surgery [14]. According to the JST
guidelines, surgery should be performed after 3–6 months
of chemotherapy in expectation of the limited but possible
efficacy of chemotherapy and the reduction of bacterial
load [4]. The procedure of choice is pulmonary resection;
segmental or greater resection is warranted if either dis-
seminated foci surround the affected lesions or if the
lesions disseminate into airways because the lesions can
extend through the airways. Chemotherapy should be
continued for at least 1 year after surgery in accordance
with the ATS/IDSA guidelines for medical therapy (i.e., for
at least 1 year after sputum conversion) [3], and on the
basis of previous experience. The National Clinical Data-
base established in 2011 can provide information about a
patient’s age, gender, and type of pulmonary resection, but
other relevant information remains missing. To perform a
more in-depth analysis of the current status of NTM sur-
gery, we need to conduct a national survey on this disease.
Conclusions
The JATS annual survey revealed a steady increase in the
annual number of operations for pulmonary NTM disease
in Japan. Japanese General Thoracic surgeons will continue
to increasingly encounter NTM patients who are candidates
for resectional surgery until a magic bullet against this
intractable disease is available. A national survey focusing
on this disease is needed for more in-depth analysis of the
current status of NTM surgery.
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